Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
Vor Biopharma Inc. (VOR)
Company Research
Source: GlobeNewswire
Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trialsDespite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials. The data, which was presented at the TANDEM Meetings of ASTCT and CIBMTR, demonstrated the need to improve the process and experience of patients considering and enrolling in CGT trials. “This original research emphasizes the unique challenges involved in offering and educating patients about cell and gene therapy trials and also highlights
Show less
Read more
Impact Snapshot
Event Time:
VOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VOR alerts
High impacting Vor Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
VOR
News
- Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at JPMorgan Chase & Co. from $43.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- Vor Biopharma (NASDAQ:VOR) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat
- Vor Bio Announces $150 Million Private PlacementGlobeNewswire
- Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage [Yahoo! Finance]Yahoo! Finance
- Vor Biopharma (NASDAQ:VOR) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $43.00 price target on the stock.MarketBeat
VOR
Earnings
- 11/13/25 - Miss
VOR
Sec Filings
- 12/19/25 - Form 4
- 12/19/25 - Form 4
- 12/19/25 - Form 4
- VOR's page on the SEC website